NasdaqCM:CELCBiotechs
Celcuity Expands VIKTORIA-2 Trial As Shares Trade Below Targets
Celcuity (NasdaqCM:CELC) amended its pivotal Phase 3 VIKTORIA-2 trial to add a new cohort for endocrine-sensitive breast cancer.
The company is also developing a subcutaneous formulation of gedatolisib to offer a more convenient treatment option.
These updates extend the clinical reach of VIKTORIA-2 beyond previously discussed trial and financing milestones.
For investors tracking Celcuity, the latest clinical updates come after a sharp pullback in the share price, which is down 29.4% over...